{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:02:59Z","timestamp":1790683379885,"version":"4.1.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-21-1-0468"],"award-info":[{"award-number":["W81XWH-21-1-0468"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40744-026-00879-6","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T18:31:14Z","timestamp":1788546674000},"page":"1223-1240","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Updates on the Evaluation of Lupus Arthritis"],"prefix":"10.1007","volume":"13","author":[{"given":"Wei","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Nordmann-Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Khalili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Rosas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Montgomery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurel","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Clancy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4597-5023","authenticated-orcid":false,"given":"Anca D.","family":"Askanase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"issue":"4","key":"879_CR1","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.berh.2009.04.003","volume":"23","author":"JM Grossman","year":"2009","unstructured":"Grossman JM. Lupus arthritis. Best Pract Res Clin Rheumatol. 2009;23(4):495\u2013506. https:\/\/doi.org\/10.1016\/j.berh.2009.04.003.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"9","key":"879_CR2","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1136\/ard.57.9.540","volume":"57","author":"RM Van Vugt","year":"1998","unstructured":"Van Vugt RM, Derksen RHWM, Kater L, Bijlsma JWJ. Deforming arthropathy or lupus and rhupus hands in systemic lupus erythematosus. Ann Rheum Dis. 1998;57(9):540\u20134. https:\/\/doi.org\/10.1136\/ard.57.9.540.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"879_CR3","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.autrev.2012.09.004","volume":"12","author":"C Tani","year":"2013","unstructured":"Tani C, D\u2019Aniello D, Delle Sedie A, et al. Rhupus syndrome: assessment of its prevalence and its clinical and instrumental characteristics in a prospective cohort of 103 SLE patients. Autoimmun Rev. 2013;12(4):537\u201341. https:\/\/doi.org\/10.1016\/j.autrev.2012.09.004.","journal-title":"Autoimmun Rev"},{"issue":"5","key":"879_CR4","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1177\/0961203319836717","volume":"28","author":"D Jesus","year":"2019","unstructured":"Jesus D, Rodrigues M, Matos A, Henriques C, Pereira Da Silva JA, In\u00eas LS. Performance of SLEDAI-2K to detect a clinically meaningful change in SLE disease activity: a 36\u2013month prospective cohort study of 334 patients. Lupus. 2019;28(5):607\u201312. https:\/\/doi.org\/10.1177\/0961203319836717.","journal-title":"Lupus"},{"issue":"1","key":"879_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2019-000365","volume":"6","author":"A Thanou","year":"2019","unstructured":"Thanou A, James JA, Arriens C, et al. Scoring systemic lupus erythematosus (SLE) disease activity with simple, rapid outcome measures. Lupus Sci Med. 2019;6(1):e000365. https:\/\/doi.org\/10.1136\/lupus-2019-000365.","journal-title":"Lupus Sci Med"},{"issue":"1","key":"879_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2014-000075","volume":"2","author":"A Askanase","year":"2015","unstructured":"Askanase A, Li X, Pong A, et al. Preliminary test of the LFA rapid evaluation of activity in lupus (LFA-REAL): an efficient outcome measure correlates with validated instruments. Lupus Sci Med. 2015;2(1):e000075. https:\/\/doi.org\/10.1136\/lupus-2014-000075.","journal-title":"Lupus Sci Med"},{"issue":"9","key":"879_CR7","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1177\/09612033231183273","volume":"32","author":"T David","year":"2023","unstructured":"David T, Su L, Cheng Y, et al. Predictors of British Isles Lupus Assessment Group-based outcomes in patients with systemic lupus erythematosus: analysis from the systemic lupus international collaborating clinics inception cohort. Lupus. 2023;32(9):1043\u201355. https:\/\/doi.org\/10.1177\/09612033231183273.","journal-title":"Lupus"},{"issue":"1","key":"879_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2020-000419","volume":"7","author":"MF Ugarte-Gil","year":"2020","unstructured":"Ugarte-Gil MF, Gamboa-Cardenas RV, Re\u00e1tegui-Sokolova C, et al. Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): data from the Peruvian Almenara Lupus Cohort. Lupus Sci Med. 2020;7(1):e000419. https:\/\/doi.org\/10.1136\/lupus-2020-000419.","journal-title":"Lupus Sci Med"},{"issue":"7","key":"879_CR9","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1002\/acr.23445","volume":"70","author":"AD Askanase","year":"2018","unstructured":"Askanase AD, Nguyen SC, Costenbader K, et al. Comparison of the lupus foundation of america-rapid evaluation of activity in lupus to more complex disease activity instruments as evaluated by clinical investigators or real-world clinicians. Arthritis Care Res. 2018;70(7):1058\u201363. https:\/\/doi.org\/10.1002\/acr.23445.","journal-title":"Arthritis Care Res"},{"key":"879_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/acr.80034","author":"A Nordmann-Gomes","year":"2026","unstructured":"Nordmann-Gomes A, Msn LK, Aranow C, et al. Comparative performance of LFA-REAL, SLEDAI, and BILAG for detecting clinically meaningful changes in lupus activity. Arthritis Care Res. 2026. https:\/\/doi.org\/10.1002\/acr.80034.","journal-title":"Arthritis Care Res"},{"issue":"6","key":"879_CR11","doi-asserted-by":"publisher","first-page":"3556","DOI":"10.1093\/rheumatology\/keae695","volume":"64","author":"K Mahmoud","year":"2025","unstructured":"Mahmoud K, Md Yusof MY, Teh LS, et al. Improving the arthritis component of the SLEDAI-2K. Rheumatology (Oxford). 2025;64(6):3556\u201362. https:\/\/doi.org\/10.1093\/rheumatology\/keae695.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"879_CR12","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1177\/0961203319834671","volume":"28","author":"A Di Matteo","year":"2019","unstructured":"Di Matteo A, Isidori M, Corradini D, et al. Ultrasound in the assessment of musculoskeletal involvement in systemic lupus erythematosus: state of the art and perspectives. Lupus. 2019;28(5):583\u201390. https:\/\/doi.org\/10.1177\/0961203319834671.","journal-title":"Lupus"},{"issue":"7","key":"879_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/biom11070928","volume":"11","author":"H Yu","year":"2021","unstructured":"Yu H, Nagafuchi Y, Fujio K. Clinical and immunological biomarkers for systemic lupus erythematosus. Biomolecules. 2021;11(7):928. https:\/\/doi.org\/10.3390\/biom11070928.","journal-title":"Biomolecules"},{"issue":"1","key":"879_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-016-1192-x","volume":"18","author":"M Ziegelasch","year":"2016","unstructured":"Ziegelasch M, van Delft MAM, Wallin P, et al. Antibodies against carbamylated proteins and cyclic citrullinated peptides in systemic lupus erythematosus: results from two well-defined European cohorts. Arthritis Res Ther. 2016;18(1):289. https:\/\/doi.org\/10.1186\/s13075-016-1192-x.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"879_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-016-1125-8","volume":"18","author":"M Piga","year":"2016","unstructured":"Piga M, Saba L, Gabba A, et al. Ultrasonographic assessment of bone erosions in the different subtypes of systemic lupus erythematosus arthritis: comparison with computed tomography. Arthritis Res Ther. 2016;18(1):222. https:\/\/doi.org\/10.1186\/s13075-016-1125-8.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"879_CR16","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1177\/0961203317713141","volume":"27","author":"L Massaro","year":"2018","unstructured":"Massaro L, Ceccarelli F, Colasanti T, et al. Anti-carbamylated protein antibodies in systemic lupus erythematosus patients with articular involvement. Lupus. 2018;27(1):105\u201311. https:\/\/doi.org\/10.1177\/0961203317713141.","journal-title":"Lupus"},{"issue":"5","key":"879_CR17","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1136\/ard-2022-223568","volume":"82","author":"LJ O\u2019Neil","year":"2023","unstructured":"O\u2019Neil LJ, Oliveira CB, Wang X, et al. Neutrophil extracellular trap-associated carbamylation and histones trigger osteoclast formation in rheumatoid arthritis. Ann Rheum Dis. 2023;82(5):630\u20138. https:\/\/doi.org\/10.1136\/ard-2022-223568.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"879_CR18","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1177\/0961203310392432","volume":"20","author":"G\u00d8 Eilertsen","year":"2011","unstructured":"Eilertsen G\u00d8, Nikolaisen C, Becker-Merok A, Nossent JC. Interleukin-6 promotes arthritis and joint deformation in patients with systemic lupus erythematosus. Lupus. 2011;20(6):607\u201313. https:\/\/doi.org\/10.1177\/0961203310392432.","journal-title":"Lupus"},{"issue":"1","key":"879_CR19","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1177\/0961203313512882","volume":"23","author":"EMA Ball","year":"2014","unstructured":"Ball EMA, Gibson DS, Bell AL, Rooney MR. Plasma IL-6 levels correlate with clinical and ultrasound measures of arthritis in patients with systemic lupus erythematosus. Lupus. 2014;23(1):46\u201356. https:\/\/doi.org\/10.1177\/0961203313512882.","journal-title":"Lupus"},{"issue":"1","key":"879_CR20","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/cei.13585","volume":"205","author":"N Sippl","year":"2021","unstructured":"Sippl N, Faustini F, R\u00f6nnelid J, et al. Arthritis in systemic lupus erythematosus is characterized by local IL-17A and IL-6 expression in synovial fluid. Clin Exp Immunol. 2021;205(1):44\u201352. https:\/\/doi.org\/10.1111\/cei.13585.","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"879_CR21","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1136\/annrheumdis-2016-209668","volume":"76","author":"DJ Wallace","year":"2017","unstructured":"Wallace DJ, Strand V, Merrill JT, et al. Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase\u00a0II dose-ranging randomised controlled trial. Ann Rheum Dis. 2017;76(3):534\u201342. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209668.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"879_CR22","doi-asserted-by":"publisher","first-page":"4218","DOI":"10.1093\/rheumatology\/keaa915","volume":"60","author":"M Piga","year":"2021","unstructured":"Piga M, Congia M, Balestrieri A, et al. Imbalanced MMP-3 and MMP-12 serum levels in systemic lupus erythematosus patients with Jaccoud\u2019s arthropathy and a distinctive MRI pattern. Rheumatology. 2021;60(9):4218\u201328. https:\/\/doi.org\/10.1093\/rheumatology\/keaa915.","journal-title":"Rheumatology"},{"issue":"6","key":"879_CR23","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1177\/0961203317753557","volume":"27","author":"DS Ribeiro","year":"2018","unstructured":"Ribeiro DS, Lins CF, Galv\u00e3o V, et al. Association of CXCL13 serum level and ultrasonographic findings of joints in patients with systemic lupus erythematosus and Jaccoud\u2019s arthropathy. Lupus. 2018;27(6):939\u201346. https:\/\/doi.org\/10.1177\/0961203317753557.","journal-title":"Lupus"},{"issue":"1","key":"879_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-74391-4","volume":"10","author":"EL Hubbard","year":"2020","unstructured":"Hubbard EL, Catalina MD, Heuer S, et al. Analysis of gene expression from systemic lupus erythematosus synovium reveals myeloid cell-driven pathogenesis of lupus arthritis. Sci Rep. 2020;10(1):17361. https:\/\/doi.org\/10.1038\/s41598-020-74391-4.","journal-title":"Sci Rep"},{"issue":"5","key":"879_CR25","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1002\/art.22578","volume":"56","author":"A Nzeusseu Toukap","year":"2007","unstructured":"Nzeusseu Toukap A, Galant C, Theate I, et al. Identification of distinct gene expression profiles in the synovium of patients with systemic lupus erythematosus. Arthritis Rheum. 2007;56(5):1579\u201388. https:\/\/doi.org\/10.1002\/art.22578.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"879_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0122104","volume":"10","author":"BR Lauwerys","year":"2015","unstructured":"Lauwerys BR, Hern\u00e1ndez-Lobato D, Gramme P, et al. Heterogeneity of synovial molecular patterns in patients with arthritis. PLoS One. 2015;10(4):e0122104. https:\/\/doi.org\/10.1371\/journal.pone.0122104.","journal-title":"PLoS One"},{"issue":"4","key":"879_CR27","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.gendis.2022.11.006","volume":"10","author":"RM Clancy","year":"2023","unstructured":"Clancy RM, Guthridge CJ, Marion MC, et al. The modifying influence of HLA class II DQB1\u221706:02 on the Streptococcus and clinical phenotype correlation among anti-Ro+ mothers of children with neonatal lupus. Genes Dis. 2023;10(4):1169\u201371. https:\/\/doi.org\/10.1016\/j.gendis.2022.11.006.","journal-title":"Genes Dis"},{"issue":"10","key":"879_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/biology11101402","volume":"11","author":"N Zemanova","year":"2022","unstructured":"Zemanova N, Omelka R, Mondockova V, Kovacova V, Martiniakova M. Roles of gut microbiome in bone homeostasis and its relationship with bone-related diseases. Biology (Basel). 2022;11(10):1402. https:\/\/doi.org\/10.3390\/biology11101402.","journal-title":"Biology (Basel)"},{"issue":"784","key":"879_CR29","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adj6294","volume":"17","author":"K Gronke","year":"2025","unstructured":"Gronke K, Nguyen M, Fuhrmann H, et al. Translocating gut pathobiont Enterococcus gallinarum induces TH17 and IgG3 anti-RNA-directed autoimmunity in mouse and human. Sci Transl Med. 2025;17(784):eadj6294. https:\/\/doi.org\/10.1126\/scitranslmed.adj6294.","journal-title":"Sci Transl Med"},{"key":"879_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2025.1565416","volume":"15","author":"X Chu","year":"2025","unstructured":"Chu X, Li S, Wang Y, et al. Alteration in gut microbiota accompanied by increased intestinal permeability and Tfh\/Tfr imbalance in patients with active SLE. Front Cell Infect Microbiol. 2025;15:1565416. https:\/\/doi.org\/10.3389\/fcimb.2025.1565416.","journal-title":"Front Cell Infect Microbiol"},{"issue":"1","key":"879_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000599","volume":"9","author":"S Xiang","year":"2022","unstructured":"Xiang S, Qu Y, Qian S, et al. Association between systemic lupus erythematosus and disruption of gut microbiota: a meta-analysis. Lupus Sci Med. 2022;9(1):e000599. https:\/\/doi.org\/10.1136\/lupus-2021-000599.","journal-title":"Lupus Sci Med"},{"key":"879_CR32","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.89300","author":"A Vineesh","year":"2025","unstructured":"Vineesh A, Shah S, Shah K, et al. Exploring the relationship between gut health and autoimmune diseases: a systematic review and meta-analysis. Cureus. 2025. https:\/\/doi.org\/10.7759\/cureus.89300.","journal-title":"Cureus"},{"issue":"16","key":"879_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/nu15163503","volume":"15","author":"V Faerber","year":"2023","unstructured":"Faerber V, Kuhn KS, Garneata L, et al. The microbiome and protein carbamylation: potential targets for protein-restricted diets supplemented with ketoanalogues in predialysis chronic kidney disease. Nutrients. 2023;15(16):3503. https:\/\/doi.org\/10.3390\/nu15163503.","journal-title":"Nutrients"},{"key":"879_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2025.152661","volume":"71","author":"W Tang","year":"2025","unstructured":"Tang W, Khalili L, Gong R, et al. Advanced imaging in the evaluation of lupus arthritis: a systematic literature review and meta-analysis. Semin Arthritis Rheum. 2025;71:152661. https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152661.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"879_CR35","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000495","volume":"8","author":"A Marone","year":"2021","unstructured":"Marone A, Tang W, Kim Y, et al. Evaluation of SLE arthritis using frequency domain optical imaging. Lupus Sci Med. 2021;8(1):e000495. https:\/\/doi.org\/10.1136\/lupus-2021-000495.","journal-title":"Lupus Sci Med"},{"issue":"2","key":"879_CR36","first-page":"329","volume":"27","author":"A Ossandon","year":"2009","unstructured":"Ossandon A, Iagnocco A, Alessandri C, Priori R, Conti F, Valesini G. Ultrasonographic depiction of knee joint alterations in systemic lupus erythematosus. Clin Exp Rheumatol. 2009;27(2):329\u201332.","journal-title":"Clin Exp Rheumatol"},{"issue":"12","key":"879_CR37","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1093\/rheumatology\/kes226","volume":"51","author":"A Gabba","year":"2012","unstructured":"Gabba A, Piga M, Vacca A, et al. Joint and tendon involvement in systemic lupus erythematosus: an ultrasound study of hands and wrists in 108 patients. Rheumatology (Oxford). 2012;51(12):2278\u201385. https:\/\/doi.org\/10.1093\/rheumatology\/kes226.","journal-title":"Rheumatology (Oxford)"},{"key":"879_CR38","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X211073001","author":"A Dima","year":"2022","unstructured":"Dima A, Jurcut C, Chasset F, Felten R, Arnaud L. Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge. Ther Adv Musculoskelet Dis. 2022. https:\/\/doi.org\/10.1177\/1759720X211073001.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"879_CR39","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead576","author":"\u00d3R Pe\u00f1a-Vizcarra","year":"2023","unstructured":"Pe\u00f1a-Vizcarra \u00d3R, Zavala-Miranda MF, Ju\u00e1rez-Cuevas B, et al. Effect of antimalarials on clinical outcomes in lupus nephritis. Rheumatology (Oxford). 2023. https:\/\/doi.org\/10.1093\/rheumatology\/kead576.","journal-title":"Rheumatology (Oxford)"},{"issue":"2 Suppl 1","key":"879_CR40","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/s0049-0172(10)80012-5","volume":"23","author":"RI Fox","year":"1993","unstructured":"Fox RI. Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin Arthritis Rheum. 1993;23(2 Suppl 1):82\u201391. https:\/\/doi.org\/10.1016\/s0049-0172(10)80012-5.","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"879_CR41","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1111\/j.1365-2125.1989.tb03439.x","volume":"27","author":"SE Tett","year":"1989","unstructured":"Tett SE, Cutler DJ, Day RO, Brown KF. Bioavailability of hydroxychloroquine tablets in healthy volunteers. Br J Clin Pharmacol. 1989;27(6):771\u20139. https:\/\/doi.org\/10.1111\/j.1365-2125.1989.tb03439.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"879_CR42","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1007\/s10067-021-05988-x","volume":"41","author":"AR Prata","year":"2022","unstructured":"Prata AR, Lu\u00eds M, Assun\u00e7\u00e3o H, da Silva JAP, In\u00eas LS. Antimalarial treatment and minimizing prednisolone are associated with lower risk of infection in SLE: a 24-month prospective cohort study. Clin Rheumatol. 2022;41(4):1069\u201378. https:\/\/doi.org\/10.1007\/s10067-021-05988-x.","journal-title":"Clin Rheumatol"},{"issue":"3","key":"879_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0320353","volume":"20","author":"S Wang","year":"2025","unstructured":"Wang S, Ka M, Wu W. Does hydroxychloroquine reduce the risk of infection in patients with systemic lupus erythematosus? A systematic review and meta-analysis. PLoS One. 2025;20(3):e0320353. https:\/\/doi.org\/10.1371\/journal.pone.0320353.","journal-title":"PLoS One"},{"key":"879_CR44","doi-asserted-by":"publisher","DOI":"10.1002\/acr.25690","author":"LR Sammaritano","year":"2025","unstructured":"Sammaritano LR, Askanase A, Bermas BL, et al. 2025 American College of Rheumatology (ACR) guideline for the treatment of systemic lupus erythematosus. Arthritis Care Res. 2025. https:\/\/doi.org\/10.1002\/acr.25690.","journal-title":"Arthritis Care Res"},{"issue":"3","key":"879_CR45","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1191\/096120301666080831","volume":"10","author":"EI Sato","year":"2001","unstructured":"Sato EI. Methotrexate therapy in systemic lupus erythematosus. Lupus. 2001;10(3):162\u20134. https:\/\/doi.org\/10.1191\/096120301666080831.","journal-title":"Lupus"},{"issue":"4","key":"879_CR46","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1177\/096120339700600407","volume":"6","author":"Y Kipen","year":"1997","unstructured":"Kipen Y, Littlejohn GO, Morand EF. Methotrexate use in systemic lupus erythematosus. Lupus. 1997;6(4):385\u20139. https:\/\/doi.org\/10.1177\/096120339700600407.","journal-title":"Lupus"},{"issue":"3","key":"879_CR47","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41584-020-0373-9","volume":"16","author":"BN Cronstein","year":"2020","unstructured":"Cronstein BN, Aune TM. Methotrexate and its mechanisms of action in inflammatory arthritis. Nat Rev Rheumatol. 2020;16(3):145\u201354. https:\/\/doi.org\/10.1038\/s41584-020-0373-9.","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"879_CR48","first-page":"243","volume":"25","author":"P Rahman","year":"1998","unstructured":"Rahman P, Humphrey-Murto S, Gladman DD, Urowitz MB. Efficacy and tolerability of methotrexate in antimalarial resistant lupus arthritis. J Rheumatol. 1998;25(2):243\u20136.","journal-title":"J Rheumatol"},{"issue":"6","key":"879_CR49","first-page":"1275","volume":"26","author":"JR Carneiro","year":"1999","unstructured":"Carneiro JR, Sato EI. Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus. J Rheumatol. 1999;26(6):1275\u20139.","journal-title":"J Rheumatol"},{"issue":"19","key":"879_CR50","first-page":"4423","volume":"21","author":"QS Zhou","year":"2017","unstructured":"Zhou QS, Hu J, Hu H. Analysis of changes in joint function and peripheral blood mononuclear cells in patients with systemic lupus erythematosus and intervention effects of different drugs. Eur Rev Med Pharmacol Sci. 2017;21(19):4423\u201330.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"879_CR51","unstructured":"Mohammadi O, Kassim TA. Azathioprine. In: StatPearls. Treasure Island: StatPearls; 2025. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK542190\/. Accessed Feb 17, 2026."},{"key":"879_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1463429","volume":"15","author":"A Krawczyk","year":"2024","unstructured":"Krawczyk A, Krav\u010denia B, Ma\u015blanka T. Mycophenolate mofetil: an update on its mechanism of action and effect on lymphoid tissue. Front Immunol. 2024;15:1463429. https:\/\/doi.org\/10.3389\/fimmu.2024.1463429.","journal-title":"Front Immunol"},{"issue":"3","key":"879_CR53","doi-asserted-by":"publisher","first-page":"552","DOI":"10.3899\/jrheum.150779","volume":"43","author":"K Tselios","year":"2016","unstructured":"Tselios K, Gladman DD, Su J, Urowitz MB. Mycophenolate mofetil in nonrenal manifestations of systemic lupus erythematosus: an observational cohort study. J Rheumatol. 2016;43(3):552\u20138. https:\/\/doi.org\/10.3899\/jrheum.150779.","journal-title":"J Rheumatol"},{"issue":"9","key":"879_CR54","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1136\/annrheumdis-2016-210882","volume":"76","author":"J Ordi-Ros","year":"2017","unstructured":"Ordi-Ros J, S\u00e1ez-Comet L, P\u00e9rez-Conesa M, et al. Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial. Ann Rheum Dis. 2017;76(9):1575\u201382. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210882.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"879_CR55","doi-asserted-by":"publisher","first-page":"317","DOI":"10.4103\/0976-500X.85930","volume":"2","author":"AK Dubey","year":"2011","unstructured":"Dubey AK, Handu SS, Dubey S, Sharma P, Sharma KK, Ahmed QM. Belimumab: first targeted biological treatment for systemic lupus erythematosus. J Pharmacol Pharmacother. 2011;2(4):317\u20139. https:\/\/doi.org\/10.4103\/0976-500X.85930.","journal-title":"J Pharmacol Pharmacother"},{"issue":"6","key":"879_CR56","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.25887","volume":"14","author":"A Joy","year":"2022","unstructured":"Joy A, Muralidharan A, Alfaraj M, Shantharam D, Cherukuri ASS, Muthukumar A. The role of belimumab in systemic lupus erythematosis: a systematic review. Cureus. 2022;14(6):e25887. https:\/\/doi.org\/10.7759\/cureus.25887.","journal-title":"Cureus"},{"issue":"11","key":"879_CR57","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1136\/annrheumdis-2011-200831","volume":"71","author":"S Manzi","year":"2012","unstructured":"Manzi S, S\u00e1nchez-Guerrero J, Merrill JT, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase\u00a0III trials. Ann Rheum Dis. 2012;71(11):1833\u20138. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200831.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"879_CR58","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ard.2025.08.016","volume":"85","author":"N Leuchten","year":"2026","unstructured":"Leuchten N, Parodis I, Brinks R, Aringer M. Belimumab induces early and sustained resolution of lupus arthritis. Ann Rheum Dis. 2026;85(2):391\u20132. https:\/\/doi.org\/10.1016\/j.ard.2025.08.016.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"879_CR59","doi-asserted-by":"publisher","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","volume":"1","author":"RA Furie","year":"2019","unstructured":"Furie RA, Morand EF, Bruce IN, et al. Type\u00a0I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase\u00a03 trial. Lancet Rheumatol. 2019;1(4):e208\u201319. https:\/\/doi.org\/10.1016\/S2665-9913(19)30076-1.","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"879_CR60","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2018-000284","volume":"5","author":"JT Merrill","year":"2018","unstructured":"Merrill JT, Furie R, Werth VP, et al. Anifrolumab effects on rash and arthritis: impact of the type\u00a0I interferon gene signature in the phase\u00a0IIb MUSE study in patients with systemic lupus erythematosus. Lupus Sci Med. 2018;5(1):e000284. https:\/\/doi.org\/10.1136\/lupus-2018-000284.","journal-title":"Lupus Sci Med"},{"issue":"3","key":"879_CR61","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1912196","volume":"382","author":"EF Morand","year":"2020","unstructured":"Morand EF, Furie R, Tanaka Y, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382(3):211\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1912196.","journal-title":"N Engl J Med"},{"issue":"15","key":"879_CR62","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1056\/NEJMoa2410965","volume":"392","author":"RA Furie","year":"2025","unstructured":"Furie RA, Rovin BH, Garg JP, et al. Efficacy and safety of obinutuzumab in active lupus nephritis. N Engl J Med. 2025;392(15):1471\u201383. https:\/\/doi.org\/10.1056\/NEJMoa2410965.","journal-title":"N Engl J Med"},{"key":"879_CR63","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2516150","author":"RA Furie","year":"2026","unstructured":"Furie RA, Dall\u2019Era M, Vital EM, et al. Efficacy and safety of obinutuzumab in active systemic lupus erythematosus. N Engl J Med. 2026. https:\/\/doi.org\/10.1056\/NEJMoa2516150.","journal-title":"N Engl J Med"},{"issue":"10143","key":"879_CR64","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","volume":"392","author":"DJ Wallace","year":"2018","unstructured":"Wallace DJ, Furie RA, Tanaka Y, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase\u00a02 trial. Lancet. 2018;392(10143):222\u201331. https:\/\/doi.org\/10.1016\/S0140-6736(18)31363-1.","journal-title":"Lancet"},{"issue":"10381","key":"879_CR65","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/S0140-6736(22)02607-1","volume":"401","author":"EF Morand","year":"2023","unstructured":"Morand EF, Vital EM, Petri M, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase\u00a03 trial (SLE-BRAVE-I). Lancet. 2023;401(10381):1001\u201310. https:\/\/doi.org\/10.1016\/S0140-6736(22)02607-1.","journal-title":"Lancet"},{"issue":"10381","key":"879_CR66","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0140-6736(22)02546-6","volume":"401","author":"M Petri","year":"2023","unstructured":"Petri M, Bruce IN, D\u00f6rner T, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase\u00a03 trial (SLE-BRAVE-II). Lancet. 2023;401(10381):1011\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(22)02546-6.","journal-title":"Lancet"},{"issue":"2","key":"879_CR67","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/art.42391","volume":"75","author":"E Morand","year":"2023","unstructured":"Morand E, Pike M, Merrill JT, et al. Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase\u00a0II, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2023;75(2):242\u201352. https:\/\/doi.org\/10.1002\/art.42391.","journal-title":"Arthritis Rheumatol"},{"issue":"6972","key":"879_CR68","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/nature02284","volume":"427","author":"M Matloubian","year":"2004","unstructured":"Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor\u00a01. Nature. 2004;427(6972):355\u201360. https:\/\/doi.org\/10.1038\/nature02284.","journal-title":"Nature"},{"issue":"6","key":"879_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2023.104775","volume":"299","author":"C Weigel","year":"2023","unstructured":"Weigel C, Bellaci J, Spiegel S. Sphingosine-1-phosphate and its receptors in vascular endothelial and lymphatic barrier function. J Biol Chem. 2023;299(6):104775. https:\/\/doi.org\/10.1016\/j.jbc.2023.104775.","journal-title":"J Biol Chem"},{"issue":"1","key":"879_CR70","doi-asserted-by":"publisher","first-page":"265","DOI":"10.7150\/thno.90940","volume":"14","author":"S Zhou","year":"2024","unstructured":"Zhou S, Zhao G, Chen R, et al. Lymphatic vessels: roles and potential therapeutic intervention in rheumatoid arthritis and osteoarthritis. Theranostics. 2024;14(1):265\u201382. https:\/\/doi.org\/10.7150\/thno.90940.","journal-title":"Theranostics"},{"key":"879_CR71","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00526","volume":"6","author":"X Huang","year":"2015","unstructured":"Huang X, Dorta-Estremera S, Yao Y, Shen N, Cao W. Predominant role of plasmacytoid dendritic cells in stimulating systemic autoimmunity. Front Immunol. 2015;6:526. https:\/\/doi.org\/10.3389\/fimmu.2015.00526.","journal-title":"Front Immunol"},{"issue":"9-10","key":"879_CR72","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.imbio.2009.06.013","volume":"214","author":"W Vermi","year":"2009","unstructured":"Vermi W, Lonardi S, Morassi M, et al. Cutaneous distribution of plasmacytoid dendritic cells in lupus erythematosus. Selective tropism at the site of epithelial apoptotic damage. Immunobiology. 2009;214(9\u201310):877\u201386. https:\/\/doi.org\/10.1016\/j.imbio.2009.06.013.","journal-title":"Immunobiology"},{"issue":"4","key":"879_CR73","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa2118024","volume":"387","author":"VP Werth","year":"2022","unstructured":"Werth VP, Furie RA, Romero-Diaz J, et al. Trial of anti-BDCA2 antibody litifilimab for cutaneous lupus erythematosus. N Engl J Med. 2022;387(4):321\u201331. https:\/\/doi.org\/10.1056\/NEJMoa2118024.","journal-title":"N Engl J Med"},{"issue":"10","key":"879_CR74","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1056\/NEJMoa2118025","volume":"387","author":"RA Furie","year":"2022","unstructured":"Furie RA, van Vollenhoven RF, Kalunian K, et al. Trial of anti-BDCA2 antibody litifilimab for systemic lupus erythematosus. N Engl J Med. 2022;387(10):894\u2013904. https:\/\/doi.org\/10.1056\/NEJMoa2118025.","journal-title":"N Engl J Med"},{"issue":"11","key":"879_CR75","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1056\/NEJMoa2106535","volume":"386","author":"JT Merrill","year":"2022","unstructured":"Merrill JT, Werth VP, Furie R, et al. Phase\u00a02 trial of iberdomide in systemic lupus erythematosus. N Engl J Med. 2022;386(11):1034\u201345. https:\/\/doi.org\/10.1056\/NEJMoa2106535.","journal-title":"N Engl J Med"},{"key":"879_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2025.152786","volume":"74","author":"A Nordmann-Gomes","year":"2025","unstructured":"Nordmann-Gomes A, Khalili L, Tang W, et al. CAR T-cell therapy in SLE: a systematic review. Semin Arthritis Rheum. 2025;74:152786. https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152786.","journal-title":"Semin Arthritis Rheum"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-026-00879-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-026-00879-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-026-00879-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:29:52Z","timestamp":1790681392000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-026-00879-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":76,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["879"],"URL":"https:\/\/doi.org\/10.1007\/s40744-026-00879-6","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"assertion":[{"value":"17 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Wei Tang, Alberto Nordmann-Gomes, Leila Khalili, Giovana Rosas, Ellen Montgomery, Laurel Zhang, Stephen Suh, and Robert Clancy have nothing to disclose. Anca D Askanase has grants or contracts from AstraZeneca, BMS, Cabaletta, Idorsia, Genentech, NKARTA, Sana, Sanofi, and UCB; consulting fees from Abbvie, Amgen, AstraZeneca, Aurinia, Biogen, BMS, Cabaletta, Celgene, Eli Lilly, Idorsia, Janssen, Genentech, GSK, Mallinckrodt, NKARTA, Pfizer, Sana, Sanofi, and UCB. Anca Askanase is an Editorial Board member of\n                      Rheumatology and Therapy\n                      . Anca Askanase was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}